|
Sunitinib Clinical Trials
12 actively recruiting trials across 7 locations
Also known as: SU11248, Sunitinib Malate, Sutent
Pipeline
Phase 1: 1Phase 2: 7Phase 3: 2Phase 1/2: 2
Top Sponsors
- University of Miami1
- University of Colorado, Denver1
- The Netherlands Cancer Institute1
- RayzeBio, Inc.1
- Rabin Medical Center1
Indications
- Cancer12
- Osteosarcoma2
- Advanced Solid Tumors2
- Lymphoma, Non-Hodgkin2
- Multiple Myeloma2
Other4 trials
Birmingham, Alabama2 trials
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
University of Alabama at Birmingham Cancer Center
Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
University of Alabama at Birmingham Comprehensive Cancer Center
Phase 2
Huntsville, Alabama1 trial
Pan Tumor Rollover Study
Local Institution - 0220
Phase 2
Phoenix, Arizona1 trial
Los Angeles, California1 trial
Losartan + Sunitinib in Treatment of Osteosarcoma
Children's Hospital Los Angeles
Phase 1
Miami, Florida1 trial
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
University of Miami
Phase 2
Boston, Massachusetts1 trial
Basking Ridge, New Jersey1 trial
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.